These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

581 related articles for article (PubMed ID: 19068246)

  • 41. Deadly proposal: a case of catecholaminergic polymorphic ventricular tachycardia.
    Heiner JD; Bullard-Berent JH; Inbar S
    Pediatr Emerg Care; 2011 Nov; 27(11):1065-8. PubMed ID: 22068070
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Catecholaminergic polymorphic ventricular tachycardia: A paradigm to understand mechanisms of arrhythmias associated to impaired Ca(2+) regulation.
    Cerrone M; Napolitano C; Priori SG
    Heart Rhythm; 2009 Nov; 6(11):1652-9. PubMed ID: 19879546
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Familial evaluation in catecholaminergic polymorphic ventricular tachycardia: disease penetrance and expression in cardiac ryanodine receptor mutation-carrying relatives.
    van der Werf C; Nederend I; Hofman N; van Geloven N; Ebink C; Frohn-Mulder IM; Alings AM; Bosker HA; Bracke FA; van den Heuvel F; Waalewijn RA; Bikker H; van Tintelen JP; Bhuiyan ZA; van den Berg MP; Wilde AA
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):748-56. PubMed ID: 22787013
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Calsequestrin mutations and catecholaminergic polymorphic ventricular tachycardia.
    Faggioni M; Kryshtal DO; Knollmann BC
    Pediatr Cardiol; 2012 Aug; 33(6):959-67. PubMed ID: 22421959
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Inhibition of cardiac Ca2+ release channels (RyR2) determines efficacy of class I antiarrhythmic drugs in catecholaminergic polymorphic ventricular tachycardia.
    Hwang HS; Hasdemir C; Laver D; Mehra D; Turhan K; Faggioni M; Yin H; Knollmann BC
    Circ Arrhythm Electrophysiol; 2011 Apr; 4(2):128-35. PubMed ID: 21270101
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Disruption of calcium homeostasis and arrhythmogenesis induced by mutations in the cardiac ryanodine receptor and calsequestrin.
    Liu N; Priori SG
    Cardiovasc Res; 2008 Jan; 77(2):293-301. PubMed ID: 18006488
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Postmortem molecular analysis for fatal arrhythmogenic disease in sudden unexplained death.
    Nishio H; Suzuki K
    Leg Med (Tokyo); 2009 Apr; 11 Suppl 1():S119-20. PubMed ID: 19261510
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Mechanism underlying catecholaminergic polymorphic ventricular tachycardia and approaches to therapy.
    Watanabe H; Knollmann BC
    J Electrocardiol; 2011; 44(6):650-5. PubMed ID: 21872879
    [TBL] [Abstract][Full Text] [Related]  

  • 49. [Catecholaminergic polymorphic ventricular tachycardia].
    Leren IS; Haugaa KH; Edvardsen T; Anfinsen OG; Kongsgård E; Berge KE; Leren TP; Amlie JP
    Tidsskr Nor Laegeforen; 2010 Jan; 130(2):139-42. PubMed ID: 20125202
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Ryanodine receptors and ventricular arrhythmias: emerging trends in mutations, mechanisms and therapies.
    George CH; Jundi H; Thomas NL; Fry DL; Lai FA
    J Mol Cell Cardiol; 2007 Jan; 42(1):34-50. PubMed ID: 17081562
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Catecholaminergic Polymorphic Ventricular Tachycardia.
    Kim CW; Aronow WS; Dutta T; Frenkel D; Frishman WH
    Cardiol Rev; 2020; 28(6):325-331. PubMed ID: 31934898
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Guidelines for the diagnosis and management of Catecholaminergic Polymorphic Ventricular Tachycardia.
    Pflaumer A; Davis AM
    Heart Lung Circ; 2012 Feb; 21(2):96-100. PubMed ID: 22119737
    [TBL] [Abstract][Full Text] [Related]  

  • 53. In situ confocal imaging in intact heart reveals stress-induced Ca(2+) release variability in a murine catecholaminergic polymorphic ventricular tachycardia model of type 2 ryanodine receptor(R4496C+/-) mutation.
    Chen B; Guo A; Gao Z; Wei S; Xie YP; Chen SR; Anderson ME; Song LS
    Circ Arrhythm Electrophysiol; 2012 Aug; 5(4):841-9. PubMed ID: 22722659
    [TBL] [Abstract][Full Text] [Related]  

  • 54. The cardiac ryanodine receptor luminal Ca2+ sensor governs Ca2+ waves, ventricular tachyarrhythmias and cardiac hypertrophy in calsequestrin-null mice.
    Zhang J; Chen B; Zhong X; Mi T; Guo A; Zhou Q; Tan Z; Wu G; Chen AW; Fill M; Song LS; Chen SR
    Biochem J; 2014 Jul; 461(1):99-106. PubMed ID: 24758151
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Unzipping RyR2 in adult cardiomyocytes: getting closer to mechanisms of inherited ventricular arrhythmias?
    Fernandez-Velasco M; Gomez AM; Richard S
    Cardiovasc Res; 2006 Jun; 70(3):407-9. PubMed ID: 16690043
    [No Abstract]   [Full Text] [Related]  

  • 56. Pathogenic mechanism of a catecholaminergic polymorphic ventricular tachycardia causing-mutation in cardiac calcium release channel RyR2.
    Xiong J; Liu X; Gong Y; Zhang P; Qiang S; Zhao Q; Guo R; Qian Y; Wang L; Zhu L; Wang R; Hao Z; Wen H; Zhang J; Tang K; Zang WF; Yuchi Z; Chen H; Chen SRW; Zheng W; Wang SQ; Xu YW; Liu Z
    J Mol Cell Cardiol; 2018 Apr; 117():26-35. PubMed ID: 29477366
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Linking calsequestrin to lumenal control of SR Ca2+ release.
    Shannon TR
    Circ Res; 2007 Sep; 101(6):539-41. PubMed ID: 17872471
    [No Abstract]   [Full Text] [Related]  

  • 58. Bradycardia Is a Specific Phenotype of Catecholaminergic Polymorphic Ventricular Tachycardia Induced by RYR2 Mutations.
    Miyata K; Ohno S; Itoh H; Horie M
    Intern Med; 2018 Jul; 57(13):1813-1817. PubMed ID: 29434162
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Molecular and tissue mechanisms of catecholaminergic polymorphic ventricular tachycardia.
    Wleklinski MJ; Kannankeril PJ; Knollmann BC
    J Physiol; 2020 Jul; 598(14):2817-2834. PubMed ID: 32115705
    [TBL] [Abstract][Full Text] [Related]  

  • 60. High prevalence of exercise-induced arrhythmias in catecholaminergic polymorphic ventricular tachycardia mutation-positive family members diagnosed by cascade genetic screening.
    Haugaa KH; Leren IS; Berge KE; Bathen J; Loennechen JP; Anfinsen OG; Früh A; Edvardsen T; Kongsgård E; Leren TP; Amlie JP
    Europace; 2010 Mar; 12(3):417-23. PubMed ID: 20106799
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 30.